Trial reportCancer2025
Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France.
Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trial
- Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.British journal of cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundMaintenance treatment with vinorelbine and oral cyclophosphamide (oral-CPM) improves outcome of nonmetastatic high-risk (HR) and very-high risk (VHR) rhabdomyosarcoma (RMS) patients. However, gonadal toxicity of maintenance was not yet investigated.
methodsThe authors focused their analysis on male gonadal toxicity in HR/VHR groups of RMS2005 trial, in France. In the HR group, patients were randomized to receive or not receive 6 months of maintenance (after nine or four IVADo] + five IVA). In the VHR group, patients received 6 months of maintenance (after four IVADo + five IVA). Exocrine gonadal dysfunction (EGD) was defined as followed: follicle-stimulating hormone level >10 IU/L and/or inhibin-B <80 pg/mL and/or oligoasthenozoospermia/azoospermia.
resultsAmong 86 eligible 5-year RMS survivors ≥12 years old, 49 had available gonadal evaluation (median age at diagnosis = 6.4 years, median age at evaluation = 18.7 years, 41 HR/8 VHR). Twenty-six (53%) received oral-CPM (median cumulative dose = 4.2 g/m
conclusionsOral-CPM induces additional gonadal damage to the ifosfamide-based induction regimen. Fertility preservation could be considered in patients exposed to maintenance, especially those >5 years old and exposed to ≥12 months of oral-CPM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.